Testimony from the Bedside: From Coleyʹs Toxins to Targeted Immunotherapy

A new clinical study reported in the New England Journal of Medicine unveils the long-awaited outcome of anti-CTLA-4 therapy for melanoma. It provides grounds for continued enthusiasm for cancer immunotherapy, deepens our thoughts on underlying mechanisms, and suggests exciting next steps.